Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced a discussion regarding its New DMT Stroke Clinical Research Program, featuring CEO Christopher J. Moreau and CSO Dr. Mark Williams, hosted on the BioPub webcast. Scheduled for February 3, 2021, at 12 PM EST, the event welcomes shareholders, investors, and the public to engage in the dialogue about Algernon's innovative approaches in drug repurposing aimed at addressing significant medical needs.
- Announcement of a new clinical research program focusing on DMT for stroke.
- Involvement of top executives in public discussion enhances transparency.
- None.
VANCOUVER, British Columbia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s New DMT Stroke Clinical Research Program on an upcoming BioPub webcast.
The BioPub webcast will be held Wednesday February 3, 2021 hosted by Dr. KSS at Noon EST. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.
BioPub has been analyzing small-cap special situation biotech investments for seven years to readers in over 40 countries.
When: February 3, 2021 12:00 PM Eastern Time (U.S. and Canada)
Topic: Algernon Welcomes DMT “The Spirit Molecule”
Please click the link below to join the webinar:
https://us02web.zoom.us/j/82026282530
Or iPhone one-tap:
US: +13126266799,,82026282530# or +16465588656,,82026282530#
Or Telephone:
Dial (for higher quality, dial a number based on your current location):
US: +1 312 626 6799 or +1 646 558 8656 or +1 301 715 8592 or +1 346 248 7799 or +1 669 900 9128 or +1 253 215 8782
Webinar ID: 820 2628 2530
International numbers available: https://us02web.zoom.us/u/kBh0SFXG5
About BioPub
BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don't get and presence at meetings others don't bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is the focus of the DMT Stroke Clinical Research Program by Algernon Pharmaceuticals?
When is the BioPub webcast scheduled?
Who will be presenting at the upcoming BioPub webcast?
How can I join the Algernon Pharmaceuticals webcast?
What is Algernon Pharmaceuticals' approach to drug development?
